Clinical trials recruiting for Pulmonary arterial hypertension

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• 129 Xenon Imaging in Patients Treated With Sotatercept
  NCT06351345 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
  NCT06104228 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
  NCT07218029 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 135 locations
• A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)
  NCT06481852 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia
  NCT07312227 · Phase: Not specified · Ages: 18 Years to 45 Years · Sex: Female · 2 locations
• A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
  NCT07143448 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)
  NCT07646860 · Phase: Phase 2 · Ages: 1 Year to 17 Years · Sex: All (male and female) · 3 locations
• A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension
  NCT06554301 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
  NCT07481981 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 20 locations
• A Trial of "APL-9796'' in Adults With Pulmonary Hypertension
  NCT06846554 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 6 locations
• An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
  NCT07365332 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 43 locations
• Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension
  NCT05566002 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization
  NCT06954727 · Phase: Not specified · Ages: 14 Years and older · Sex: All (male and female) · 1 location
• DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
  NCT07623525 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• DataBase of pulmoNary hyPertesion in PoLish Population - BNP-PL
  NCT03959748 · Phase: Not specified · Ages: 3 Months and older · Sex: All (male and female) · 1 location
• Exercise Capacity Muscle Oxygenation and Arterial Stiffness in Children With Pulmonary Arterial Hypertension
  NCT06454838 · Phase: Not specified · Ages: 6 Years to 18 Years · Sex: All (male and female) · 1 location
• Exercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial Hypertension
  NCT07366879 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Exercise-based Rehabilitation in Patients With Pulmonary Arterial Hypertension
  NCT06804122 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
  NCT07613099 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 1 location
• FreeFlow Percutaneous Atrial Septal Shunt for IPAH
  NCT06605794 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions
  NCT02691689 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
  NCT06528418 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female) · 2 locations
• Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
  NCT06317805 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 19 locations
• Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH
  NCT06350032 · Phase: Phase 3 · Ages: Up to 18 Years · Sex: All (male and female) · 5 locations
• Mobile Health Intervention to Improve Exercise in Pediatric PH
  NCT06549452 · Phase: Not applicable (e.g. observational or device study) · Ages: 10 Years to 21 Years · Sex: All (male and female) · 1 location
• Multimodality RV Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 PAH
  NCT07667673 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• National Registry and Cohort Study of Pulmonary Vascular Disease
  NCT05368467 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 13 locations
• Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
  NCT06274801 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 120 locations
• PET Image in PAH Patients
  NCT05452889 · Phase: Early Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
  NCT02249923 · Phase: Not specified · Ages: 1 Day to 21 Years · Sex: All (male and female) · 14 locations
• Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
  NCT04278404 · Phase: Not specified · Ages: 0 Years to 20 Years · Sex: All (male and female) · 52 locations
• PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArch
  NCT06998329 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Pulmonary Hypertension Association Registry
  NCT04071327 · Phase: Not specified · Ages: 0 Years and older · Sex: All (male and female) · 52 locations
• Pulmonary Hypertension Biorepository and Registry
  NCT04808596 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Pulmonary Hypertension SOLAR
  NCT04778046 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Quantifying 18kDa TSPO Expression in the Lung in Pulmonary Artery Hypertension (PAH)
  NCT05745961 · Phase: Not specified · Ages: 25 Years to 75 Years · Sex: All (male and female) · 1 location
• REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE)
  NCT05665556 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Repurposing Valsartan May Protect Against Pulmonary Hypertension
  NCT06053580 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)
  NCT06658522 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Rutgers University Study of the Genetics of Pulmonary Hypertension
  NCT07217522 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Spironolactone for Pulmonary Arterial Hypertension
  NCT01712620 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 1 location
• Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
  NCT05587712 · Phase: Phase 2 · Ages: 1 Year to 17 Years · Sex: All (male and female) · 35 locations
• Taiwan Interstitial Lung Disease Multi-center Investigation and Registry
  NCT06476470 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension
  NCT07013149 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
  NCT05464095 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
  NCT04555161 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
  NCT04062565 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Xenon MRI Pulm Hypertension
  NCT04991454 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce
  NCT06850792 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for Pulmonary arterial hypertension often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Pulmonary arterial hypertension trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.